PITTSBURGH — Mylan on Monday announced the launch of its generic of Dexedrine (dextroamphetamine sulfate) extended-release capsules. The drug is indicated to treat narcolepsy and attention deficit disorder with hyperactivity as part of a treatment plan including other measure in patients 6 to 16 years of age.
Mylan’s generic will be available in 5-, 10- and 15-mg dosage strengths. The product had U.S. sales of about $101.3 million for the 12 months ended May 31, according to IMS Health data.